Areas of Focus
- Tumor Pharmacology
- Tumor Biology
Work Experience
- 2015-10~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher
- 2011-10~2015-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher
- 2009-07~2011-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Assistant Researcher
Academic Background & Achievements
- 2006-09--2009-06 PhD: Ocean University of China
- 2003-09--2006-06 Master's: Ocean University of China
- 1999-09--2003-06 Bachelor's: Ocean University of China
Publications
- Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors, JOURNAL OF MEDICINAL CHEMISTRY, 2023
- SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer, Signal Transduction and Targeted Therapy, 2023
- Discovery of 10H-Benzobpyrido2,3-e1,4oxazine AXL Inhibitors via Structure-Based Drug Design Targeting c-Met Kinase, JOURNAL OF MEDICINAL CHEMISTRY, 2022
- Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors, JOURNAL OF MEDICINAL CHEMISTRY, 2022
- F-18-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis, THERANOSTICS, 2022
- Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor, JOURNAL OF MEDICINAL CHEMISTRY, 2021
- Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage, JOURNAL OF MEDICINAL CHEMISTRY, 2021
- Design, synthesis and biological evaluation of pyrazolo3,4-dpyridazinone derivatives as covalent FGFR inhibitors, ACTA PHARMACEUTICA SINICA B, 2021
- The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation, MOLECULAR CANCER THERAPEUTICS, 2021
- Discovery of pyrrolo2,3-dpyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021
- Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models., CANCER IMMUNOLOGY RESEARCH, 2020
- Discovery and Development of a Series of Pyrazolo3,4-dpyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design, JOURNAL OF MEDICINAL CHEMISTRY, 2019
- The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors, MOLECULAR CANCER THERAPEUTICS, 2019
- Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo2,3-bpyrazine scaffold: structure-activity relationship, crystal structural characterization and and in vivo study, ACTA PHARMACEUTICA SINICA B, 2019
- Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019
- Discovery of a potent tyrosine kinase AXL inhibitor bearing the 3-((2,3,4,5-tetrahydro-1H-benzo d azepin-7-yl)amino)pyrazine core, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019
- Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes (FXRPD)-P-high-L1(low) NSCLC to Anti-PD-1 Immunotherapy, CANCER IMMUNOLOGY RESEARCH, 2019
- Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019
- Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019
- Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and in Vivo Antitumor Profiles, CHEMICAL RESEARCH IN TOXICOLOGY, 2018
- Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors (vol 61, pg 9085, 2018), JOURNAL OF MEDICINAL CHEMISTRY, 2018
- somcl085anovelmultitargetedfgfrinhibitordisplayspotentanticanceractivityinfgfraddictedhumancancermodels, ACTA PHARMACOLOGICA SINICA, 2018
- Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018
- Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018
- Structure-Based Discovery of a Series of 5H-Pyrrolo2,3-bpyrazine FGFR Kinase Inhibitors, MOLECULES, 2018
- Structure-Based Discovery of a Series of 5H-Pyrrolo2,3-bpyrazine FGFR Kinase Inhibitors, MOLECULES, 2018
- Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models, MOLECULAR CANCER THERAPEUTICS, 2018
- Discovery and Biological Evaluation of a Series of Pyrrolo2,3- b pyrazines as Novel FGFR Inhibitors, MOLECULES : A JOURNAL OF SYNTHETIC CHEMISTRY AND NATURAL PRODUCT CHEMISTRY, 2017
- Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer., ACTA PHARMACOLOGICA SINICA, 2017
- Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer, JOURNAL OF MEDICINAL CHEMISTRY, 2017
- Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017
- Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer, 中国药理学报：英文版, 2017
- Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma, HEPATOLOGY, 2017
- Palladium-Catalyzed, Silver-Assisted Direct C-5-H Arylation of 3-Substituted 1,2,4-Oxadiazoles under Microwave Irradiation, ADVANCED SYNTHESIS & CATALYSIS, 2017
- Synthesis and structure���activity relationship study of pyrazolo3,4-dpyrimidines as tyrosine kinase RET inhibitors, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017
- c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors, CLINICAL CANCER RESEARCH, 2017
- Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017
- Cyanobacterial peptides as a prototype for the design of cathepsin D inhibitors, JOURNAL OF PEPTIDE SCIENCE, 2017
- Discovery and Biological Evaluation of a Series of Pyrrolo2,3-bpyrazines as Novel
Awards
- China Patent Silver Award (2023): Second Prize, National Level
- Shanghai Workers' Excellent Innovation Achievement Award (2019): Second Prize, Other
- Shanghai Pharmaceutical Science and Technology Award (2017): First Prize, Municipal Level
- Sanofi-Shanghai Institute of Biological Sciences Outstanding Young Talent Award (2014): Institute Level
- Shanghai Institute of Materia Medica 'Outstanding Young Scientific Worker' (2014): Institute Level
- Chinese Pharmacological Society Servier Young Pharmacologist Award (2012): Other
